Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 300 of 974 publications.

Kukafka R, Fang J, Vanegas A, Silverman T, Crew KD. Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting. BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134. doi: 10.1186/s12911-018-0716-5

Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R. An applied framework in support of shared decision making about BRCA genetic testing. AMIA Annu Symp Proc. 2018 Dec 5;2018:961-9.

Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R. Automatic genetic risk assessment calculation using breast cancer family history data from the EHR compared to self-report. AMIA Annu Symp Proc. 2018 Dec 5;2018:970-8.

Auclair D, Mansfield C, Chari A, Cole CE, Fiala MA, Kaufman JL, Orloff G, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Patient treatment preferences for relapsed/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability? Presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 3, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):614. doi: 10.1182/blood-2018-99-113087

Kabadi S, Goyal RK, Nagar SP, Kaye JA, Davis KL, Mato A. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):3557. doi: 10.1182/blood-2018-99-114735

Kawai AT, Martinez D, Saltus CW, Vassilev Z, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in men with castration-resistant prostate cancer. Poster presented at the Palliative and Supportive Care in Oncology Symposium; November 17, 2018. San Diego, CA. [abstract] J Clin Oncol. 2018 Nov 28; 36(34_suppl):188. doi: 10.1200/JCO.2018.36.34_suppl.188

Kurosky S, Levine C, Kaye JA, Esterberg E, Suarez LA, Zhan L, Iyer S. HR+/HER2− advanced breast cancer treatment, disease progression, and survival in Argentina, Brazil, Chile, Colombia, and Mexico. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.

Parikh R, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Mann H, Wang H. Treatments and health care utilisation (HCU) in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) following initial platinum therapy in the United Kingdom. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.

Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H. Treatments and health care utilisation (HCU) following initial platinum therapy in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): a medical record review in Germany. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.

Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H. Assessment of treatments and health care utilisation (HCU) in Spain following initial platinum therapy for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.

Goyal R, Nagar S, Davis KL, Kaye JA. Time trends in frontline systemic therapy utilization for chronic lymphocytic leukemia in the United States. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.

Crawford R, Bell T, Rushton R, Doward L. A critique of YouTube™ as a data source for the qualitative exploration of patient-reported information on acute myeloid leukemia. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Osorio J, Jerico C, Miranda C, Garsot E, Luna A, Miro M, Santamaria M, Artigau E, Rodriguez-Santiago J, Castro S, Feliu J, Aldeano A, Olona C, Momblan D, Ruiz D, Galofre G, Pros I, Garcia-Albeniz X, Lozano M, Pera M. Perioperative transfusion management in gastric cancer surgery: analysis of the Spanish subset of the EURECCA oesophago-gastric cancer registry. Cir Esp. 2018 Nov;96(9):546-54. doi: 10.1016/j.ciresp.2018.03.010

Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, Strickler JH. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. J Med Econ. 2018 Nov;21(11):1075-83. doi: 10.1080/13696998.2018.1510409.

Gable J, Ayer D, Girvan A, Bowman L, Abada P, Ervin C, Evans E, Cella D. Qualitative patient interviews to support the FACT hepatobiliary symptom index-8 among patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 2018. Barcelona, Spain.

De Laurentiis M, Davis KL, Ajmera M, Mitra D, Nuzzo CMA, Harbeck N. Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Poster presented at the European Society for Medical Oncology (ESMO) 43rd Congress 2018; October 22, 2018. Munich, Germany.

Goyal RK, Kron A, Wolf J, Mazieres J, Chouaid C, Davis KL, Perrinjaquet M, Knoll S. Treatment patterns and overall survival in patients with BRAF-mutated metastatic non-small cell lung cancer. Poster presented at the European Society for Medical Oncology (ESMO) 43rd Congress 2018; October 20, 2018. Munich, Germany.

Haque R, Shi JM, Telford C, Avila C, Alvarado M, Tiller GE, Dalvi T, Gutierrez L, Tyczynski J, Kaye JA. Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Perm J. 2018 Oct 11;22:17-197. doi: 10.7812/TPP/17-197

Iyer S, Darden C, McSorley D, Davis K, Band J, Mitra D. Treatment satisfaction in young women receiving palbociclib combination therapies for advanced/metastatic breast cancer in multiple countries globally. Poster presented at the 4th ESO-ESMO Breast Cancer in Young Women International Conference; October 6, 2018. Lugano, Switzerland.

Joish VN, Price MA, Schwartz S, Stanley S, Bennett L, Darden C, Tesfaye E, Mobley Q, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: a real-world evidence study evaluating patient-reported outcomes with Xermelo. Poster presented at the 2018 NANETS Annual Multidisciplinary NET Disease Symposium; October 4, 2018. Seattle, WA.

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A, Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review. Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8

Odom D, Mitra D, Hollis K, Richardson D, Kaye J, McRoy L. A prospective observational study of mobile application-based Patient-Reported Outcomes (PRO) in advanced breast cancer: interim baseline data from the MADELINE study. Poster presented at the 2018 ESMO Congress; October 2018. Munich, Germany.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Saif W, Parikh R, Ray D, Kaye JA, Kurosky S, Thomas S, Halfdanarson T, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the NANETS Regional NET Education Conference; September 15, 2018. New Brunswick, NJ. Previously presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Mytelka DS, Nagar SP, D'yachkova Y, La EM, Kaye JA, Candrilli SD, Kasper B, Lopez-Martin JA, Lorenzo M. Health care resource utilization and costs among adult patients with advanced soft tissue sarcoma: a retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018 Sep 12;2018:2020591. doi: 10.1155/2018/2020591

La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862

Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care. BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x

Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736

Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.

Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J, Manzano H, Mendez JC, Zanui M, Falco E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Garcia-Albeniz X, Maurel J. Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients. Neoplasia. 2018 Jul;20(7):678-86. doi: 10.1016/j.neo.2018.05.004

Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 Jul;122(1):50-8.

Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal. 2018 Jun 28;6(2):9-20.

Harris D, Midkiff K, Gilsenan A, Andrews E. Linking big (federal) data to state cancer registry data for a post-marketing drug safety surveillance study: challenges and lessons learned. Presented at the 2018 Annual Conference of the North American Association of Central Cancer Registries (NAACCR); June 12, 2018. Pittsburgh, PA.

Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD. Understanding factors associated with uptake of BRCA1/2 genetic testing among Orthodox Jewish women in the USA using a mixed-methods approach. Public Health Genomics. 2018 Jun;21(5-6):186-96. doi: 10.1159/000499852

Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174

Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544

Nagar S, Mytelka D, Candrilli SD, D'yachkova Y, Lorenzo M, Kasper B, Lopez-Martin J, Kaye JA. Treatment patterns and survival among adult patients with advanced soft tissue sarcoma: a retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018 May 24;2018. doi: 10.1155/2018/5467057

Mitra D, Darden C, McSorley D, Davis K, Band J, Iyer S. Patient reported treatment satisfaction with palbociclib combination therapies for HR+/HER2– advanced or metastatic breast cancer in multiple countries. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120

Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x

Trantham L, Klein AB, Parikh RC, Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289

Jackson JW, Garcia-Albeniz X. Studying the effects of nonindicated medications on cancer: etiologic versus action-focused analysis of epidemiologic data. Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):520-4. doi: 10.1158/1055-9965.EPI-17-0862

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291

Kurosky S, Klein AB, Parikh RC, Trantham L, Zhang Y, Levine CA, Kaye JA. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.286

Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222

Zhou X, Eid D, Gnanasakthy A. Methods for reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S226. doi: 10.1016/j.jval.2018.04.1528

Parikh RC, Klein AB, Kurosky S, Trantham L, Zhang Y, Levine CA, Kaye JA. Programmed cell death LIGAND-1 testing among patients with metastatic non-small cell lung cancer: a multinational medical record review study. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S50. doi: 10.1016/j.jval.2018.04.1821